Vincerx Pharma (NASDAQ:VINC) vs. BeyondSpring (NASDAQ:BYSI) Financial Review

BeyondSpring (NASDAQ:BYSI) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares BeyondSpring and Vincerx Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	N/A
Vincerx Pharma	N/A	-226.84%	-122.94%

Risk and Volatility

BeyondSpring has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for BeyondSpring and Vincerx Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	0	0	0	0	N/A
Vincerx Pharma	0	0	1	0	3.00

Insider & Institutional Ownership

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 22.9% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares BeyondSpring and Vincerx Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.88 million	45.98	-$21.03 million	N/A	N/A
Vincerx Pharma	N/A	N/A	-$40.16 million	($1.79)	-0.39

BeyondSpring has higher revenue and earnings than Vincerx Pharma.

Summary

BeyondSpring beats Vincerx Pharma on 5 of the 8 factors compared between the two stocks.

About BeyondSpring

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.